IBM reported on 3/11/2019 that it used machine learning to identify sets of proteins in blood that are predictive of a biomarker in spinal fluid. This new type of blood testing is not only an effective and noninvasive diagnostic technology for early-onset Alzheimer's, but also the first to use a machine learning approach. Patent data further indicate IBM's commitment to using artificial intelligence in the biotech sector.
